TerminatedNot Applicable

Effect of Modified Mirror Therapy in Patients With Upper Limb Hemiparesis After Stroke

Stopped: Ethical issues

China116 participantsStarted 2022-08-01

Plain-language summary

This was a randomized controlled study in China conducted during Aug. 2022 to Aug. 2023. Totally, patients with upper limb hemiplegia after stroke, who were admitted in the Department of Rehabilitation Medicine of two hospitals, were enrolled. The study lasted 30 days for each participant. The patients enrolled were randomly divided into the experimental group and the control group, all under routine rehabilitation therapy. Additionally, the patients in the experimental group were given modified mirror therapy.

Who can participate

Age range

35 Years – 70 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Meeting the diagnostic criteria of stroke, by CT or MRI. * The first-onset stroke. * Presenting with unilateral upper limb dysfunction, within Brunnstrom stage Ⅱ to Ⅳ on the affected side, and Ash-worth score ≤2. * No obvious cognitive impairment, with Mini-Mental State Examination (MMSE) score \>21 points. * National Institutes of Health Stroke Scale (NIHSS) score \>4 points. * Stable vital signs, no severe diseases such as cancer, liver or kidney disorders. * Aged 35-70 years. * Courses of diseases 2-6 weeks. Exclusion Criteria: * Presence of aphasia, apraxia, or hemispatial neglect. * Presence of hearing, vision, or comprehension impairments that hinder diagnosis and treatment. * Complicate with traumas, fractures, or other progressive neuro-muscular system diseases. * Severe spasticity in the upper limbs. * Severe bone, joint, or muscle deformities or lesions. * History of mental illness.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Fugl-Meyer Assessment-Upper Extremity

Timeframe: day 1 and day 30

Trial details

NCT IDNCT06199375

SponsorZeng Changhao

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-12

View on ClinicalTrials.gov More Stroke trials